5-Iodo-2-Pyrimidinone-2′-Deoxyribose-Mediated Cytotoxicity and Radiosensitization in U87 Human Glioblastoma Xenografts

In U87 human glioblastoma s.c. xenografts, p.o. IPdR given q.d. × 14 days and RT given 2 Gy/d × 4 days (days 11-14 of IPdR treatment) results in a significant tumor growth delay in an IPdR dose-dependent pattern. The use of p.o. IPdR plus RT holds promise for Phase I/II testing in patients with high-grade gliomas.